3/4 Moderate
Risk of bias. This randomized, double-blind trial used a pharmaceutical dose in people with optic nerve damage. The confidence interval was wide. The risk-of-bias assessment did not further lower confidence in the result. Consistency: One direct trial covered this population and outcome, so consistency across studies could not be assessed. There was no additional downgrade for this domain. Applicability to the stated population: The question concerns chronic vision loss in multiple sclerosis. The result cannot be extrapolated to healthy eyes. There was no additional downgrade for this domain. Precision: The study was small or the confidence interval allows for materially different effects. Possible publication bias: Too few studies were available to assess publication bias reliably. There was no additional downgrade for this domain.At six months, visual acuity in the selected eye changed by −0.061 logMAR on MD1003 and −0.036 on placebo. On this scale, a decrease means better vision. The adjusted difference was −0.01983 (95% confidence interval −0.1085 to 0.0689; p=0.66). There was no convincing advantage over placebo.
Study findings. At six months, visual acuity in the selected eye changed by −0.061 logMAR on MD1003 and −0.036 on placebo. On this scale, a decrease means better vision. The adjusted difference was −0.01983 (95% confidence interval −0.1085 to 0.0689; p=0.66). There was no convincing advantage over placebo.
Comparator: Placebo